Clinical Trial Update: Phase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase Ib/II study evaluating nivolumab with paclitaxel in EBV-related or MSI-H or PD-L1 positive advanced gastric cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• nivolumab (nivolumab)

Snippet

Sponsor: Yonsei University | Conditions: Recurrent/Metastatic Gastric Cancer | Phase 1, Phase 2 | Status: COMPLETED